Dr. Sweeney on the Future of Prostate Cancer Research

Christopher Sweeney, MBBS
Published: Tuesday, Nov 18, 2014

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

There have been several drugs approved to treat patients with castration-resistant prostate cancer: abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel. The challenge remains to determine proper combinations and sequencing. Sweeney says the oncology community needs to commit to clinical trials to answer these persisting questions.

Sweeney says he is leading a trial looking at hormonal therapy with or without enzalutamide, allowing for upfront docetaxel, in patients with hormone-sensitive disease. Sweeney believes the way forward is to combine drugs in the castration-resistant setting and use combinations earlier in the hormone-sensitive setting.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the future of prostate cancer research.

There have been several drugs approved to treat patients with castration-resistant prostate cancer: abiraterone, enzalutamide, sipuleucel-T, radium-223, and cabazitaxel. The challenge remains to determine proper combinations and sequencing. Sweeney says the oncology community needs to commit to clinical trials to answer these persisting questions.

Sweeney says he is leading a trial looking at hormonal therapy with or without enzalutamide, allowing for upfront docetaxel, in patients with hormone-sensitive disease. Sweeney believes the way forward is to combine drugs in the castration-resistant setting and use combinations earlier in the hormone-sensitive setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x